(Reuters) - Anti-tumour necrosis factor drugs have revolutionised
treatment for many patients with severe rheumatoid arthritis but
their high cost, which can exceed 10,000 pounds per
patient a year, has made NICE wary about their use.
"It is fantastic that people may now get a 'second bite of
the cherry'. There are three drugs of this type, and obviously
patients want to try the other two if the first does not work
for them," Arthritis Care head Neil Betteridge said in a
statement.
Read more at Reuters.com Government Filings News
treatment for many patients with severe rheumatoid arthritis but
their high cost, which can exceed 10,000 pounds per
patient a year, has made NICE wary about their use.
"It is fantastic that people may now get a 'second bite of
the cherry'. There are three drugs of this type, and obviously
patients want to try the other two if the first does not work
for them," Arthritis Care head Neil Betteridge said in a
statement.
Read more at Reuters.com Government Filings News
No comments:
Post a Comment